InflaRx (IFRX) earnings

Healthcare · Biotechnology · Market cap $229M

In the quarter ended June 2025, InflaRx had revenue of 39,432 EUR, and diluted EPS of -0.21.

On August 6, 2026 it reported EPS of -0.11 against an estimate of -0.08 (missed).

The next report is expected on Monday, November 9, 2026, with EPS expected around -0.07.

Report dates

ReportDateTimeEPS estimateEPS reported
NextMon Nov 9, 2026 — -0.07 —
LastThu Aug 6, 2026 — -0.08 -0.11

Dates from company announcements and exchange calendars; estimates are the consensus where available. See the full earnings calendar.

Quarterly results

The last 7 quarters from InflaRx's 10-Q and 10-K filings with the SEC, in EUR. Growth is against the same quarter a year earlier. EPS here is GAAP diluted EPS as filed; the reported EPS compared with estimates above can be on the company's adjusted basis, so the two can differ.

Quarter endedRevenueGrowthEPS (diluted)GrowthOp. marginFiled
Jun 30, 202539,432 EUR — -0.21 — — 2025-08-07
Jun 30, 20246,357 EUR — -0.24 — — 2024-08-08
Jun 30, 2023-10M EUR — -0.14 — — 2023-08-10
Jun 30, 2022-1M EUR — 0.01 — — 2022-08-05
Jun 30, 2021-14M EUR — -0.33 — — 2022-08-05
Jun 30, 2019-16M EUR — -0.59 — — 2019-08-14
Jun 30, 2018-8M EUR — -0.10 — — 2019-08-14
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for IFRX.
Open IFRX in Investingly

Questions

When does InflaRx report earnings?

InflaRx's next earnings report is expected on November 9, 2026.

How did InflaRx do last quarter?

In the quarter ended June 2025, InflaRx had revenue of 39,432 EUR, and diluted EPS of -0.21.

From InflaRx's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.